In 68 adults with laryngopharyngeal reflux disease despite anti-secretory therapy, an upper oesophageal sphincter assist device at therapeutic vs low pressure made no significant difference: primary endpoint met in 45.2% vs 53.6%. Both groups improved.
RCTn = 68
Yadlapati et al. Randomized Controlled Trial of Upper Esophageal Sphincter Assist Device in Laryngopharyngeal Reflux Disease